Drugs / AVX-COVID/12
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05710783 | Nov → Dec 2022 | COVID-19 | Laboratorio Avi-Mex, S.A. de C.V. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-05-04 | Laboratorio Avi-Mex, S.A. de C.V. | Results La etapa de desarrollo clínico del proyecto VACUNAL PATRIA® arroja datos favorables (AVX/COVID-12) com.mx ↗
La vacuna Patria® genera anticuerpos similares a una vacuna aprobada por la OMS de acuerdo con los datos disponibles de la Etapa Final de Desarrollo Clínico, como vacuna de refuerzo. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-05-04 | Laboratorio Avi-Mex, S.A. de C.V. | La etapa de desarrollo clínico del proyecto VACUNAL PATRIA® arroja datos favorables (AVX/COVID-12) com.mx ↗ |
| 2022-08-17 | Laboratorio Avi-Mex, S.A. de C.V. | Avances de la Fase Clínica II de proyecto VACUNAL PATRIA® (AVX/COVID-12) com.mx ↗ |
| 2021-11-12 | Laboratorio Avi-Mex, S.A. de C.V. | Avimex® anuncia la publicación de datos Preclínicos en cerdos de la VACUNA PATRIA® (AVX/COVID-12) com.mx ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVX/COVID-12 | “This is a phase II/III parallel, double-blind, active-controlled, non-inferiority study to evaluate immunogenicity and safety of a booster immunization scheme of a single...” NCT05710783 ↗ |
| Modality | Vaccine | “recombinant vaccine against SARS-CoV-2” NCT05710783 ↗ |
| Route | Intramuscular | “single intramuscular dose” NCT05710783 ↗ |